An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 11 May 2017
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Expanded access; Therapeutic Use
- Sponsors Genentech
- 29 Jul 2016 Status changed from suspended to recruiting.
- 06 Jul 2016 Status changed from recruiting to suspended.
- 05 Jul 2016 New trial record